The study on synergism effect of Cuminum cyminum L boiled extract with quadruple and triple therapy for eradicated helicobacter pillory

The study on synergism effect of Cuminum cyminum L boiled extract with quadruple and triple therapy for eradicated helicobacter pillory in peptic ulcer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012071510291N1

Enrollment

100

Registered

2012-09-09

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peptic ulcer disease induced with H.pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified

Interventions

Intervention 1: 5- omeprazole 20 mg bid, bismuth subcitrate 120 mg qid, amoxicillin 500mg qid, metronidazole 500 mg bid for 14 days. Intervention 2: 2 - Cuminum (3g/100cc water) b.i.d, omeprazole 20 m

Treatment - Drugs

5- omeprazole 20 mg bid, bismuth subcitrate 120 mg qid, amoxicillin 500mg qid, metronidazole 500 mg bid for 14 days.

2 - Cuminum (3g/100cc water) b.i.d, omeprazole 20 mg bid, clarithromycin 500mg bid, amoxicillin 500mg qid, for 14 days.

4- omeprazole 20 mg bid, clarithromycin 500mg bid, amoxicillin 500mg qid for 14 days

3- Cuminum (3g/100cc water) bid and omeprazole 20 mg bid, bismuth subcitrate 120 mg qid, amoxicillin 500mg qid, metronidazole 500 mg bid, for 14 days.

1- Cuminum (3g/100cc water) bid and omeprazole 20 mg bid for 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Urease test was positive; The patient's willingness to cooperate Exclusion criteria:Patients were excluded if they were pregnant; glucose-6 phosphate dehydrogenase (G6PD)-deficient; if they had a history of chronic kidney, liver or lung failure, previous gastrointestinal (GI) surgery, recent upper gastrointestinal bleeding; if they had used non-steroidal anti-inflammatory drug (NSAID) or antibiotic in the past four weeks; if they had any known allergic reaction to drugs used in the treatment regimens; if they were currently breast-feeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eridication. Timepoint: 1 month after treatment. Method of measurement: urea breath test.	—

Secondary

Measure	Time frame
Synergism effect. Timepoint: 1 month after treatment. Method of measurement: compare the results of urea breath test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Bagher Majnooni

Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah

mnikbakht@kums.ac.ir-bagher_1985@yahoo.com+98 83 1427 6473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026